Novartis Animal Health US Inc. has recalled 4,530 bottles of Deramaxx (deracoxib) chewable tablets used for pain and inflammation in dogs because the medication does not meet finished product assay specifications. The recall affects Deramaxx 25 mg tablets in 30-count and 90-count bottles, as well as Deramaxx 100 mg tablets in 90-count bottles. This means the actual amount of active medication in the tablets may differ from what is stated on the label, which could impact the effectiveness or safety of the treatment. These products were distributed in California, Georgia, and Hawaii.
If the tablets do not meet assay specifications, a dog may receive more or less of the medication than intended. This could lead to an ineffective treatment of pain or, in the case of over-potency, an increased risk of side effects associated with NSAIDs, such as gastrointestinal or kidney issues.
Drug Recall Refund/Guidance
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response